Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifaximin SSD IR · 1 trial · 2 indications
Change in SCFA in stool and serum in rifaximin SSD phase vs placebo phase
Change in bile acids in stool and serum in rifaximin SSD phase vs placebo phase
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Patients will be given placebo and actual drug sequentially with the order hidden |
| Rifaximin SSD 40mg IR BID | EXPERIMENTAL | Patients will be given placebo and actual drug sequentially with the order hidden |
| Name | Type | Description |
|---|---|---|
| Rifaximin SSD 40 mg IR tablet | DRUG | Drug therapy vs placebo |
| Placebo | DRUG | Placebo drug |
Inclusion Criteria: * Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale. * Males and Females Age ≥ 65 years * Community living with availability of caregiver to accompany participant to study visits and to participate in the study....
Rifaximin SSD IR is an investigational small molecule being studied for dementia of the Alzheimer type. It is currently in Phase 1 clinical development for this neurological condition. The drug is being evaluated in a clinical trial that also includes patients with dementia associated with cerebrovascular disease.
Rifaximin SSD IR is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is conducting a Phase 1 clinical trial of the drug in the United States for dementia of the Alzheimer type.
Rifaximin SSD IR is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is currently recruiting participants in the United States.
Rifaximin SSD IR is being studied in a Phase 1 clinical trial with the identifier NCT06718686, titled "Rifaximin SSD in Dementia Trial." The trial is recruiting 20 participants aged 65 years and older in the United States and is double-blind and placebo-controlled.
Yes, Rifaximin SSD IR is also known as Rifaximin SSD 40 mg IR tablet. Both names refer to the same investigational drug being developed by Bausch + Lomb Corporation for dementia of the Alzheimer type.
Rifaximin SSD IR is a small molecule being studied for dementia of the Alzheimer type. The specific molecular target of the drug has not been disclosed in the available clinical trial information, so its mechanism of action is not described here.